S41 Case Report: Immunoglobulin G4-Related Disease Mistaken for Crohn’s Disease

Abstract

and adalimumab (0.003), and ustekinumab/vedolizumab (0.002). We also looked at outcomes of the patients who had HF as an adverse event due to biologics, including hospitalizations and it showed it was highest with adalimumab,followed by In fl iximab and vedolizumab. The other outcome we looked at was mortality for patients who had HF with biologics, it was highest in patients who had used adalimumab, followed by In fl iximab and ustekinumab. Conclusions: Our study adds further to the literature regarding biologics adverse events, speci fi cally heart failure. Tofacitinib had the highest ratio of heart failure among all adverse e ff ects, followed by the already-established In fl iximab. All other newer biologics had a relatively lower ratio. Despite tofacitinibhavingthehighestratioforheartfailure,wecannotattributesigni fi cancetothisduetothis drug having only one reported case compared to other drugs. Furthermore, we can conclude that newer biologics have a relatively very small ratio for the risk of heart failure compared to In fl iximab. Further data is needed for the newer biologics.